Silo pharma completes successful dose-ranging study of spc-15 intranasal therapeutic for ptsd

All animal subjects tolerated maximum dosing once-per-day human intranasal dosing regimen determined for clinical evaluation sarasota, fl, feb. 28, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-glp small animal dose-ranging study of spc-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (ptsd). the purpose of the non-glp small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials.
SILO Ratings Summary
SILO Quant Ranking